Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 6/20 | 0.60 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.52 |
| ▸ | STK17B | O94768 | 1/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | GALR2 | O43603 | 1/20 | 0.42 |
| ▸ | GALR1 | P47211 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033896 | 0.93 | BCL6 (0.57) | BCL6BCDIN3DSTK17BSTK17AMAPT | |
| SCHEMBL4836573 | 0.89 | BCL6 (0.68) | BCL6MAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL4839482 | 0.89 | BCL6 (0.60) | BCL6MAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL5550961 | 0.87 | BCL6 (0.58) | BCL6STK17BSTK17AMAPTGAA | |
| SCHEMBL4836855 | 0.87 | BCL6 (0.54) | BCL6STK17BSTK17AMAPTGAA | |
| SCHEMBL4838606 | 0.86 | SMN1; SMN2 (0.64) | BCL6MAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL4829781 | 0.86 | RAB9A (0.65) | BCL6MAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL5033891 | 0.86 | BCL6 (0.51) | BCL6STK17BSTK17AMAPTGAA | |
| SCHEMBL4839296 | 0.85 | BCL6 (0.61) | BCL6MAPTGAASMN1; SMN2RAB9A | |
| SCHEMBL5029063 | 0.85 | BCL6 (0.55) | BCL6STK17BSTK17AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| WO-2005103015-A1 | TRIAZINE COMPOUNDS AND THEIR ANALOGS, COMPOSITIONS, AND METHODS | REDDY US THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-10-13 | — | — | US | claimed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335770-B2 | Triazine compounds and their analogs, compositions, and methods | REDDY U5 THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| WO-2005103015-A1 | TRIAZINE COMPOUNDS AND THEIR ANALOGS, COMPOSITIONS, AND METHODS | REDDY US THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-10-13 | — | — | US | disclosed |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227983-A1 | Triazine compounds and their analogs, compositions, and methods | MYLK, SMAD3, GID4 | BCL6 541/4885BCDIN3D 2549/4885STK17B 443/4885 |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | HTT, HMOX1, SNCA | BCL6 3286/4885BCDIN3D 3329/4885STK17B 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.